Argininosuccinate Synthase 1 (ASS1) Reagents for Synthetic Lethality & Metabolic Disorder Research. Premium-grade recombinant proteins (WT & disease mutants), lentiviral ORFs, monoclonal antibodies, siRNA sets, and metabolic assay tools for arginine deprivation therapy (ADI-PEG20) development, citrullinemia Type I drug discovery, and biomarker validation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASS1 drug discovery, metabolic vulnerability screening, and companion diagnostics.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | ASS1 Wild-Type Recombinant Protein; >95% purity, <1 EU/ug endotoxin, sequence verified, native folding for enzyme assays. | View ASS1 Products |
| Antigen (Mutant) | ASS1 Disease Variants (G324D, rs121908636; T375S, G390R); mass spec verified, for chaperone screening and thermal shift assays. | View ASS1 Products |
| Benchmark Ab | Anti-ASS1 Recombinant Monoclonal Antibody; rabbit, validated for WB/IHC/IF, ideal for IHC standardization in ASS1-deficient tumors. | View ASS1 Products |
| Gene Delivery | ASS1 Promise-ORF / Lentivirus; full-length ORF for stable cell line construction, rescue experiments in ASS1-null models. | View ASS1 Products |
| Validator | ASS1 siRNA Set; validated knockdown for synthetic lethality verification and arginine auxotrophy modeling. | View ASS1 Products |
| Metabolic Partner – ASL | Argininosuccinate Lyase; downstream urea cycle enzyme, for coupled enzymatic assays and resistance mechanism studies. | View ASL Products |
| Metabolic Partner – OTC | Ornithine Transcarbamylase; upstream urea cycle enzyme for pathway reconstruction. | View OTC Products |
| Related Target – SLC7A1 | Arginine transporter CAT1; essential for arginine deprivation mechanism and tumor uptake studies. | View SLC7A1 Products |
| Related Target – ARG1 | Arginase 1; synergistic depletion target, companion for ADI-PEG20 combination strategies. | View ARG1 Products |
| Related Target – GLS1 | Glutaminase 1; addresses metabolic escape pathways in ASS1-negative tumors via glutamine compensation. | View GLS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active enzyme for biochemical inhibitor HTS | HEK293-expressed ASS1 with native folding, >95% purity, controlled endotoxin; suitable for SPR, enzymatic kinetics, and DSF. |
| Urea cycle selectivity (off-target vs ASL/OTC) | Homolog panel proteins strictly verified by mass spec; human/mouse/cyno orthologs available for cross-species PK. |
| Cellular context for synthetic lethality rescue | Lentivirus for stable ASS1 overexpression/knockdown; validated siRNA set to confirm phenotype. |
| Biomarker IHC standardization | Recombinant anti-ASS1 monoclonal antibody with batch-to-batch consistency, ideal for CDx development. |
| Chaperone drug screening for citrullinemia | Disease mutant panel (G324D, T375S, G390R) with purity >95% for thermal shift and activity rescue assays. |
| Combination therapy assay (IO + ADT) | Full-length ASS1 lentivirus and WT protein to model ASS1 re-expression resistance in immune co-culture. |
Live ASS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Argine Deprivation & Synthetic Lethality Research
- ➤ Citrullinemia Type I Therapeutic Development
- ➤ Resistance Mechanism Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic paradigm for ASS1 has bifurcated into two distinct tracks: synthetic lethality in oncology via arginine deprivation therapy (ADT), and enzyme replacement/chaperone therapy for citrullinemia Type I. Polaris Group's ADI-PEG20 (pegylated arginine deiminase) leads the oncology space, targeting ASS1-deficient mesothelioma, hepatocellular carcinoma, and soft tissue sarcoma where epigenetic silencing of ASS1 creates arginine auxotrophy. As first-generation ADT agents face resistance mechanisms (including ASS1 re-expression and ASL upregulation), the next wave of R&D targets combination strategies with immune checkpoint inhibitors (e.g., PD-1/PD-L1) and metabolic pathway modulation (c-Myc inhibitors, glutaminase inhibitors). In the rare disease space, pharmacological chaperones to rescue misfolded ASS1 mutants (e.g., G324D) represent a precision medicine frontier requiring high-quality disease-variant proteins. ASS1 is also emerging as a premier predictive biomarker rather than merely a drug target, driving demand for standardized IHC companion diagnostics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Arginine Depletion Enzyme (ADT) | Polaris Group (ADI-PEG20), Aeglea (pegzilarginase) | Mesothelioma, HCC, Sarcoma, Melanoma | ASS1-deficient cell lines via lentiviral rescue; cross-species orthologs for PK/PD; anti-ASS1 Ab for IHC stratification |
| Small Molecule Chaperones | Academic / Early Biotech | Citrullinemia Type I | Disease mutant ASS1 proteins (G324D, T375S) for stability/activity assays (TSA, DSF, HPLC) |
| Direct Small Molecule Inhibitors | Emerging Biotech / Academia | Gastric Cancer, Ovarian Cancer (ASS1-positive) | High-purity active ASS1 for enzymatic inhibition HTS; coupled ASL assay for selectivity |
| Gene Therapy / Enzyme Replacement | Rare Disease Biotech | Urea Cycle Disorders (Citrullinemia) | Full-length ASS1 ORF lentivirus for functional complementation in patient-derived cells |
| Combination Therapy (IO + ADT) | Various Big Pharma / Biotech | Melanoma, Glioblastoma, Mesothelioma | Metabolic rescue assay (stable ASS1 overexpression lentivirus); anti-ASS1 Ab for immune microenvironment studies |
Key Disease Mutations and Chaperone Screening
Citrullinemia Type I is caused by mutations in the ASS1 gene, including G324D (dbSNP:rs121908636), T375S, G390R, and others. TarMart provides a comprehensive panel of these pathogenic mutants (strictly verified by mass spec) for pharmacological chaperone screening. Use thermal shift assays (DSF/TSA) with our recombinant mutant proteins to identify small molecules that rescue folding and restore enzymatic activity.
Strategic Cross-sell Targets
Based on the urea cycle and arginine metabolic network, the following targets complement ASS1 research:
- ASL (Argininosuccinate Lyase): Downstream enzyme; key resistance node in ADT resistance; dual-target inhibitors emerging.
- OTC (Ornithine Transcarbamylase): Upstream enzyme; needed for complete urea cycle reconstruction assays.
- SLC7A1 (CAT1): Arginine transporter; essential for understanding arginine uptake in tumors and synergy with ADT.
- ARG1 (Arginase 1): Alternative arm of arginine depletion; combination with ADI-PEG20 being explored.
- GLS1 (Glutaminase 1): Compensation pathway when arginine is low; dual blockade may overcome resistance.